Get started
Author

Diana Bello Roufai

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
2023 · Kathleen N. Moore, Antoine Angelergues, et al. · New England Journal of Medicine · 554
PDF
Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer
2021 · Emmanuelle Jeannot, Aurélien Latouche, et al. · Clinical Cancer Research · 178
PDF
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
2026 · Nicoletta Colombo, Emese Zsiros, et al. · The Lancet · 74
Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases
2024 · Alexandre De Moura, Delphine Loirat, et al. · Breast Cancer · 39
PDF
A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial
2021 · Istvan Petak, Maud Kamal, et al. · npj Precision Oncology · 30
PDF
Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial
2024 · Claire F. Friedman, Anishka D'Souza, et al. · Gynecologic Oncology · 29
PDF
Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy
2021 · Pauline Vaflard, Xavier Paoletti, et al. · Drugs in R&D · 25
PDF
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
2023 · D. Bello Roufai, A. Gonçalves, et al. · Oncogene · 23
PDF
Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial
2021 · E. de Guillebon, M. Jimenez, et al. · ESMO Open · 19
PDF
Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network
2022 · Clémence Romeo, Olivia Le Saux, et al. · Cancers · 15
PDF
Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
2024 · Elisa Yaniz-Galende, Qinghe Zeng, et al. · Clinical Cancer Research · 13
PDF
Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment
2017 · Ilan Darmon, Mony Chenda Morisse, et al. · Journal of Cancer · 10
PDF
LBA42 Raludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): Primary analysis of the phase II dose-optimization part of REJOICE-Ovarian01
2025 · I.L. Ray-Coquard, K. Hasegawa, et al. · Annals of Oncology · 7
PDF
36MO Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (OC): 5-year (y) progression-free survival (PFS) by molecular subgroup in the PAOLA-1/ENGOT-ov25 trial
2023 · A.J. Gonzalez Martin, J. Medioni, et al. · ESMO Open · 4
PDF
RAIDS atlas of significant genetic and protein biomarkers in cervical cancer
2023 · Suzy Scholl, Diana Bello Roufai, et al. · Journal of Gynecologic Oncology · 4
PDF
The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification
2024 · K. Rahmani Narj Abadi, C. Dupain, et al. · ESMO Real World Data and Digital Oncology · 3
PDF
Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
2023 · D. Bello Roufai, A. Gonçalves, et al. · Oncogene · 3
PDF
819TiP COLIBRI trial (GINECO-CE108b): A multicenter, window study evaluating immune impact and safety of nivolumab in combination with ipilimumab before initial radio-chemotherapy (RTCT) treatment for locally advanced cervix cancer
2021 · I.L. Ray-Coquard, M-C. Kaminsky-Forrett, et al. · Annals of Oncology · 3
Impact of circulating tumor DNA early detection and serial monitoring in the management of stage I to III colorectal cancer
2019 · Diana Bello Roufai, François-Clément Bidard · Annals of Translational Medicine · 3
PDF
Results of a National French Survey on use of KELIM model for management of patients with advanced stage epithelial ovarian cancer (SFOG Campus)
2025 · Diana Bello Roufai, Houssein El Hajj, et al. · Bulletin du Cancer · 2
Efficacy and safety of immune checkpoint inhibitor rechallenge in cervical and endometrial cancer: a multi-center retrospective study (RICE study)
2026 · Rayan Kabirian, Mathilde de Saint Ghislain, et al. · International Journal of Gynecological Cancer · 1
Mechanisms of drug resistance: PARP inhibitors, antibody-drug-conjugates, and immunotherapy
2025 · Diana Bello Roufai, Richard Toth, et al. · International Journal of Gynecological Cancer · 1
Place des thérapies innovantes dans la prise en charge des cancers du col de l’utérus
2023 · Diana Bello Roufai · Bulletin du Cancer · 1
Metadata record for the manuscript: A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial
2021 · Istvan Petak, Kamal, Maud, et al. · Figshare · 1
Efficacy and safety of pembrolizumab–lenvatinib in metastatic endometrial cancer: results from the French multicenter early access program
2026 · D. Bello Roufai, L. Mansi, et al. · ESMO Open
PDF
Works count: 59
Citation count: 1,042
H-index: 11
I10-index: 12
Year
Topic
Type